<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>INTERMEZZO- zolpidem tartrateÂ tabletÂ </strong><br>Purdue Pharma LP<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use INTERMEZZOÂ® safely and effectively. See full prescribing information for INTERMEZZO. <br>INTERMEZZO<span class="Sup">Â®</span> (zolpidem tartrate) sublingual tablets, CIV<br>Initial U.S. Approval: 1992</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Intermezzo is a GABA<span class="Sub">A</span> agonist indicated for use as needed for the treatment of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> when a middle-of-the-night awakening is followed by difficulty returning to sleep <a href="#Section_1">(1)</a> </p>
<p class="Highlighta"><span class="Underline">Limitation of Use</span>: Not indicated for the treatment of middle-of-the night awakening when the patient has fewer than 4 hours of bedtime remaining before the planned time of waking <a href="#Section_1">(1)</a> </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>Take only if 4 hours of bedtime remain before the planned time of waking <a href="#Section_2.1">(2.1</a>, <a href="#Section_5.1">5.1)</a>
</li>
<li>Intermezzo should be placed under the tongue and allowed to disintegrate completely before swallowing. The tablet should not be swallowed whole. <a href="#Section_2.1">(2.1)</a>
</li>
<li>The effect of Intermezzo may be slowed if taken with or immediately after a meal <a href="#Section_2.1">(2.1)</a>
</li>
<li>Recommended dose is 1.75 mg for women and 3.5 mg for men, taken only once per night if needed <a href="#Section_2.2">(2.2)</a>
</li>
<li>Lower doses of CNS depressants may be necessary when taken concomitantly with Intermezzo <a href="#Section_2.3">(2.3)</a>
</li>
<li>Co-administration with CNS depressants: Recommended dose is 1.75 mg for men and women <a href="#Section_2.3">(2.3)</a>
</li>
<li>Geriatric patients and patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>: Recommended dose is 1.75 mg for men and women <a href="#Section_2.4">(2.4</a>, <a href="#Section_2.5">2.5)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">1.75 mg and 3.5 mg sublingual tablets <a href="#Section_3">(3)</a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to zolpidem <a href="#Section_4">(4)</a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>CNS depressant effects: Impairs alertness and motor coordination. Instruct patients on correct use  <a href="#Section_5.1">(5.1)</a>
</li>
<li>Evaluate for co-morbid diagnoses: Re-evaluate if <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> persists after 7 to 10 days of use <a href="#Section_5.2">(5.2)</a>
</li>
<li>Severe anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>: <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> have been reported. Do not re-challenge if such reactions occur <a href="#Section_5.3">(5.3)</a>
</li>
<li>â€œSleep-drivingâ€? and other complex behaviors while not fully awake. Risk increases with dose and use with other CNS depressants and alcohol. Immediately evaluate any new onset behavioral changes <a href="#Section_5.4">(5.4)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>: Worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or suicidal thinking may occur. Prescribe the least number of tablets feasible to avoid <span class="product-label-link" type="condition" conceptid="4244894" conceptname="Intentional drug overdose">intentional overdose</span> <a href="#Section_5.5">(5.5)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span>: Consider this risk before prescribing in patients with compromised respiratory function <a href="#Section_5.6">(5.6)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most commonly observed adverse reactions (&gt; 1% in adult patients) are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>. <a href="#Section_6.1">(6.1)</a><br><br> </p>
<p class="Highlighta"><span class="Bold"><span class="Emphasis">To report SUSPECTED ADVERSE REACTIONS, contact Purdue Pharma at 1-888-726-7535 or FDA at 1-800-FDA-1088 or <span class="Underline">www.fda.gov/medwatch.</span></span></span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>CNS depressants, including alcohol: Possible adverse additive CNS depressant effects <a href="#Section_5.1">(5.1</a>, <a href="#Section_7.1">7.1)</a>
</li>
<li>Imipramine: Decreased alertness observed <a href="#Section_7.1">(7.1)</a>
</li>
<li>Chlorpromazine: Impaired alertness and psychomotor performance observed <a href="#Section_7.1">(7.1)</a>
</li>
<li>Rifampin: Combination use may decrease effects <a href="#Section_7.2">(7.2)</a>
</li>
<li>Ketoconazole: Combination use may increase effects <a href="#Section_7.2">(7.2)</a>
</li>
</ul></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>Pregnancy: Based on animal data, zolpidem may cause fetal harm. <a href="#Section_8.1">(8.1)</a>
</li>
<li>Pediatric use: Safety and effectiveness of Intermezzo not established. With bedtime dosing of zolpidem, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> observed (incidence 7%) <a href="#Section_8.4">(8.4)</a>
</li>
</ul></div>
<div><div></div></div>
<div></div>
<div><div></div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 9/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1â€ƒâ€ƒINDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2â€ƒâ€ƒDOSAGE AND ADMINISTRATION </a></h1>
<h2><a href="#section-2.1" class="toc">2.1â€ƒâ€ƒImportant Administration Instructions</a></h2>
<h2><a href="#section-2.2" class="toc">2.2â€ƒâ€ƒBasic Dosing Information</a></h2>
<h2><a href="#section-2.3" class="toc">2.3â€ƒâ€ƒUse with CNS Depressants </a></h2>
<h2><a href="#section-2.4" class="toc">2.4â€ƒâ€ƒUse in Geriatric Patients</a></h2>
<h2><a href="#section-2.5" class="toc">2.5â€ƒâ€ƒUse in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-3" class="toc">3â€ƒâ€ƒDOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4â€ƒâ€ƒCONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5â€ƒâ€ƒWARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1â€ƒâ€ƒCNS Depressant Effects and Next-Day Impairment </a></h2>
<h2><a href="#section-5.2" class="toc">5.2â€ƒâ€ƒNeed to Evaluate for Co-morbid Diagnoses</a></h2>
<h2><a href="#section-5.3" class="toc">5.3â€ƒâ€ƒSevere Anaphylactic and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4â€ƒâ€ƒAbnormal Thinking and Behavioral Changes </a></h2>
<h2><a href="#section-5.5" class="toc">5.5â€ƒâ€ƒUse in Patients with <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6â€ƒâ€ƒRespiratory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7â€ƒâ€ƒWithdrawal Effects</a></h2>
<h1><a href="#section-6" class="toc">6â€ƒâ€ƒADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1â€ƒâ€ƒClinical Trials Experience </a></h2>
<h2><a href="#section-6.2" class="toc">6.2â€ƒâ€ƒPost Marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7â€ƒâ€ƒDRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1â€ƒâ€ƒCNS-active Drugs</a></h2>
<h2><a href="#section-7.2" class="toc">7.2â€ƒâ€ƒDrugs that Affect Drug Metabolism via Cytochrome P450</a></h2>
<h1><a href="#section-8" class="toc">8â€ƒâ€ƒUSE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1â€ƒâ€ƒPregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3â€ƒâ€ƒNursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4â€ƒâ€ƒPediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5â€ƒâ€ƒGeriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6â€ƒâ€ƒGender Difference in Pharmacokinetics</a></h2>
<h1><a href="#section-9" class="toc">9â€ƒâ€ƒDRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></h1>
<h2><a href="#section-9.1" class="toc">9.1â€ƒâ€ƒControlled Substance</a></h2>
<h2><a href="#section-9.2" class="toc">9.2â€ƒâ€ƒAbuse</a></h2>
<h2><a href="#section-9.3" class="toc">9.3â€ƒâ€ƒDependence</a></h2>
<h1><a href="#section-10" class="toc">10â€ƒâ€ƒOVERDOSAGE</a></h1>
<h2><a href="#section-10.1" class="toc">10.1â€ƒâ€ƒSigns and Symptoms</a></h2>
<h2><a href="#section-10.2" class="toc">10.2â€ƒâ€ƒRecommended Treatment</a></h2>
<h1><a href="#section-11" class="toc">11â€ƒâ€ƒDESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12â€ƒâ€ƒCLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1â€ƒâ€ƒMechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.3â€ƒâ€ƒPharmacokinetics</a></h2>
<h2><a href="#section-12.3" class="toc"></a></h2>
<h2><a href="#section-12.4" class="toc"></a></h2>
<h1><a href="#section-13" class="toc">13â€ƒâ€ƒNONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1â€ƒâ€ƒCarcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-14" class="toc">14â€ƒâ€ƒCLINICAL STUDIES</a></h1>
<h2><a href="#section-14.1" class="toc">14.1â€ƒâ€ƒMiddle-of-the-Night Awakening Trials</a></h2>
<h2><a href="#section-14.2" class="toc">14.2â€ƒâ€ƒSpecial Safety Studies</a></h2>
<h1><a href="#section-15" class="toc">16â€ƒâ€ƒHOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17â€ƒâ€ƒPATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc"></a></h2>
<h2><a href="#section-16.2" class="toc"></a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_1"></a><a name="section-1"></a><p></p>
<h1>1â€ƒâ€ƒINDICATIONS AND USAGE</h1>
<p class="First"><a name="p23122"></a>Intermezzo<span class="Sup">Â®</span> (zolpidem tartrate) sublingual tablet is indicated for use as needed for the treatment of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> when a middle-of-the-night awakening is followed by difficulty returning to sleep.</p>
<p><a name="p30122"></a><span class="Underline"><span class="Emphasis">Limitations of Use</span></span>: Intermezzo is not indicated for the treatment of middle-of-the-night <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> when the patient has fewer than 4 hours of bedtime remaining before the planned time of waking.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_2"></a><a name="section-2"></a><p></p>
<h1>2â€ƒâ€ƒDOSAGE AND ADMINISTRATION </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1â€ƒâ€ƒImportant Administration Instructions</h2>
<p class="First"><a name="p528122"></a>Intermezzo is to be taken in bed when a patient wakes in the middle of the night and has difficulty returning to sleep. Intermezzo should only be taken if the patient has at least 4 hours of bedtime remaining before the planned time of waking <span class="Italics"><span class="Emphasis">[see Warnings and Precautions <a href="#Section_5.1">(5.1)</a>]</span></span>.</p>
<p><a name="p541122"></a>Intermezzo should be placed under the tongue and allowed to disintegrate completely before swallowing. The tablet should not be swallowed whole. For optimal effect, Intermezzo should not be administered with or immediately after a meal. The tablet should be removed from the pouch just prior to dosing.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2â€ƒâ€ƒBasic Dosing Information</h2>
<p class="First"><a name="p549122"></a>The recommended and maximum dose of Intermezzo is 1.75 mg for women and 3.5 mg for men, taken only once per night as needed if a middle-of-the-night awakening is followed by difficulty returning to sleep. The recommended doses for women and men are different because women clear zolpidem from the body at a lower rate than men<span class="Italics"><span class="Emphasis">[see Use in Specific Populations <a href="#Section_8.6">(8.6)</a>]</span></span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3â€ƒâ€ƒUse with CNS Depressants </h2>
<p class="First"><a name="p774122"></a>The recommended Intermezzo dose for men and women who are taking concomitant CNS depressants is 1.75 mg. Dose adjustment of concomitant CNS depressants may be necessary when co-administered with Intermezzo because of potentially additive effects. The use of Intermezzo with other sedative-hypnotics (including other zolpidem products) at bedtime or the middle of the night is not recommended <span class="Italics"><span class="Emphasis">[see Warnings and Precautions <a href="#Section_5.1">(5.1)</a>]</span></span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.4"></a><a name="section-2.4"></a><p></p>
<h2>2.4â€ƒâ€ƒUse in Geriatric Patients</h2>
<p class="First"><a name="p792122"></a>Geriatric patients may be especially sensitive to the effects of zolpidem. The recommended dose of Intermezzo in men and women over 65 years old is 1.75 mg, taken only once per night if needed <span class="Italics"><span class="Emphasis">[see Use in Specific Populations <a href="#Section_8.5">(8.5)</a>]</span></span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.5"></a><a name="section-2.5"></a><p></p>
<h2>2.5â€ƒâ€ƒUse in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First"><a name="p810122"></a>The recommended dose of Intermezzo in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> is 1.75 mg, taken only once per night if needed <span class="Italics"><span class="Emphasis">[see Clinical Pharmacology <a href="#Section_12.3">(12.3)</a>]</span></span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="Section_3"></a><a name="section-3"></a><p></p>
<h1>3â€ƒâ€ƒDOSAGE FORMS AND STRENGTHS</h1>
<p class="First"><a name="p1034122"></a>Intermezzo is available as 1.75 mg and 3.5 mg tablets for sublingual administration.</p>
<p><a name="p1037122"></a>Intermezzo 1.75 mg tablets are yellow, round, uncoated, biconvex, debossed with ZZ on one side.</p>
<p><a name="p1040122"></a>Intermezzo 3.5 mg tablets are beige, round, uncoated, biconvex, debossed with ZZ on one side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4"></a><a name="section-4"></a><p></p>
<h1>4â€ƒâ€ƒCONTRAINDICATIONS</h1>
<p class="First"><a name="p1056122"></a>Intermezzo is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to zolpidem. Observed reactions with zolpidem include <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> <span class="Italics"><span class="Emphasis">[see Warnings and Precautions <a href="#Section_5.3">(5.3)</a>]</span></span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5"></a><a name="section-5"></a><p></p>
<h1>5â€ƒâ€ƒWARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1â€ƒâ€ƒCNS Depressant Effects and Next-Day Impairment </h2>
<p class="First"><a name="p1539122"></a>Intermezzo, like other sedative-hypnotic drugs, has central nervous system (CNS) depressant effects. Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>. Dosage adjustments of Intermezzo and of other concomitant CNS depressants may be necessary when Intermezzo is administered with such agents because of the potentially additive effects. The use of Intermezzo with other sedative-hypnotics (including other zolpidem products) at bedtime or the middle of the night is not recommended <span class="Italics"><span class="Emphasis">[see Dosage and Administration <a href="#Section_2.3">(2.3)</a>]</span></span>.</p>
<p><a name="p1552122"></a>In a driving study, healthy subjects who received Intermezzo with fewer than four hours of bedtime remaining had evidence of impaired driving compared to subjects who received placebo <span class="Italics"><span class="Emphasis">[see Clinical Studies <a href="#Section_14.2">(14.2)</a>]</span></span>. The risk of next-day driving impairment (and psychomotor impairment) is increased if Intermezzo is taken with less than 4 hours of bedtime remaining, if higher than recommended dose is taken, if co-administered with other CNS depressants, or co-administered with other drugs that increase the blood levels of zolpidem.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2â€ƒâ€ƒNeed to Evaluate for Co-morbid Diagnoses</h2>
<p class="First"><a name="p1570122"></a>Because <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disturbances</span> may be the presenting manifestation of a physical and/or psychiatric disorder, symptomatic treatment of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> should be initiated only after a careful evaluation of the patient. <span class="Italics"><span class="Emphasis">The failure of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness that should be evaluated.</span></span> Worsening of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> or the emergence of new thinking or behavior abnormalities may be the consequence of an unrecognized psychiatric or physical disorder. Such findings have emerged during the course of treatment with sedative-hypnotic drugs, including zolpidem.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3â€ƒâ€ƒSevere Anaphylactic and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></h2>
<p class="First"><a name="p1584122"></a>Cases of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> involving the tongue, glottis, or larynx have been reported in patients after taking the first or subsequent doses of zolpidem. Some patients have had additional symptoms such as <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, throat closing, or <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> that suggest <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>. Some patients have required medical therapy in the emergency department. If <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> involves the throat, glottis or larynx, airway obstruction may occur and be fatal. Patients who develop <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> or <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> after treatment with zolpidem should not be rechallenged with Intermezzo.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4â€ƒâ€ƒAbnormal Thinking and Behavioral Changes </h2>
<p class="First"><a name="p1798122"></a><span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Abnormal thinking</span> and behavior changes have been reported in patients treated with sedative-hypnotics including zolpidem. Some of these changes included decreased inhibition (e.g., <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span> and extroversion that seemed out of character), <span class="product-label-link" type="condition" conceptid="4092397" conceptname="Bizarre behavior">bizarre behavior</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, and <span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">depersonalization</span>. Visual and <span class="product-label-link" type="condition" conceptid="4164151" conceptname="Auditory hallucinations">auditory hallucinations</span> have also been reported.</p>
<p><a name="p1801122"></a>In controlled trials of zolpidem tartrate 10 mg taken at bedtime, &lt; 1% of adults with <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> who received zolpidem reported <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>. In a clinical trial, 7% of pediatric patients treated with zolpidem tartrate 0.25 mg/kg taken at bedtime, reported <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, versus 0% treated with placebo <span class="Italics"><span class="Emphasis">[see Use in Specific Populations <a href="#Section_8.4">(8.4)</a>]</span></span>.</p>
<p><a name="p1814122"></a>Complex behaviors such as â€œsleep-drivingâ€? (i.e., driving while not fully awake after ingestion of a sedative-hypnotic, with <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span> for the event) have been reported in sedative-hypnotic-naive as well as in sedative-hypnotic-experienced persons. Although behaviors such as â€œsleep-drivingâ€? have occurred with zolpidem alone at therapeutic doses, the co-administration of zolpidem with alcohol and other CNS depressants increases the risk of such behaviors, as does the use of zolpidem at doses exceeding the maximum recommended dose. Due to the risk to the patient and the community, discontinuation of Intermezzo should be strongly considered for patients who report a â€œsleep-drivingâ€? episode.</p>
<p><a name="p1818122"></a>Other complex behaviors (e.g., preparing and eating food, making phone calls, or having sex) have been reported in patients who are not fully awake after taking a sedative-hypnotic. As with â€œsleep-drivingâ€?, patients usually do not remember these events. <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">Amnesia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> and other neuro-<span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span> may also occur.</p>
<p><a name="p1821122"></a>The emergence of any new behavioral sign or symptom of concern requires careful and immediate evaluation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5â€ƒâ€ƒUse in Patients with <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></h2>
<p class="First"><a name="p1829122"></a>In primarily depressed patients treated with sedative-hypnotics, worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and suicidal thoughts and actions (including <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">completed suicides</span>), have been reported. Suicidal tendencies may be present in such patients and protective measures may be required. Intentional overdosage is more common in this group of patients; therefore, the lowest number of tablets that is feasible should be prescribed for the patient at any one time.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6â€ƒâ€ƒRespiratory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></h2>
<p class="First"><a name="p1837122"></a>Although studies with 10 mg zolpidem tartrate did not reveal respiratory depressant effects at hypnotic doses in healthy subjects or in patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> (<span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>), a reduction in the Total Arousal Index, together with a reduction in lowest oxygen saturation and increase in the times of oxygen desaturation below 80% and 90%, was observed in patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">sleep apnea</span> when treated with zolpidem compared to placebo. Since sedative-hypnotics have the capacity to depress respiratory drive, precautions should be taken if Intermezzo is prescribed to patients with compromised respiratory function. Post-marketing reports of <span class="product-label-link" type="condition" conceptid="318459" conceptname="Respiratory insufficiency">respiratory insufficiency</span> in patients receiving 10 mg of zolpidem tartrate, most of whom had pre-existing respiratory impairment, have been reported. The risks of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> should be considered prior to prescribing Intermezzo in patients with respiratory impairment including <span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">sleep apnea</span> and <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7â€ƒâ€ƒWithdrawal Effects</h2>
<p class="First"><a name="p2051122"></a>There have been reports of withdrawal signs and symptoms following the rapid dose decrease or abrupt discontinuation of zolpidem. Monitor patients for tolerance, abuse, and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> <span class="Italics"><span class="Emphasis">[see Drug Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> <a href="#Section_9.2">(9.2)</a> and <a href="#Section_9.3">(9.3)</a>]</span></span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_6"></a><a name="section-6"></a><p></p>
<h1>6â€ƒâ€ƒADVERSE REACTIONS</h1>
<p class="First"><a name="p2073122"></a>The following serious adverse reactions in zolpidem-treated patients are discussed in greater detail in other sections of the labeling:</p>
<ul class="Disc">
<li>CNS-depressant effects and next-day impairment <span class="Italics"><span class="Emphasis">[see Warnings and Precautions <a href="#Section_5.1">(5.1)</a>]</span></span>
</li>
<li>Serious anaphylactic and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> <span class="Italics"><span class="Emphasis">[see Warnings and Precautions <a href="#Section_5.3">(5.3)</a>]</span></span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Abnormal thinking</span> and behavioral changes, and complex behaviors <span class="Italics"><span class="Emphasis">[see Warnings and Precautions <a href="#Section_5.4">(5.4)</a>]</span></span>
</li>
<li>Withdrawal effects <span class="Italics"><span class="Emphasis">[see Warnings and Precautions <a href="#Section_5.7">(5.7)</a>]</span></span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1â€ƒâ€ƒClinical Trials Experience </h2>
<p class="First"><a name="p2563122"></a>The safety data described below are based on two double-blind placebo-controlled trials of Intermezzo in adult patients with <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> characterized by difficulty returning to sleep after a middle-of-the-night awakening <span class="Italics"><span class="Emphasis">[see Clinical Studies <a href="#Section_14.1">(14.1)</a>]</span></span>. These two trials included 230 and 82 patients treated with 3.5 mg and 1.75 mg of Intermezzo, respectively. The first study was a 3-way crossover sleep-laboratory study in 82 patients (58 female and 24 male; median age 47 years; 51% Caucasian, 44% African-American) of 1.75 mg and 3.5 mg of Intermezzo compared to placebo (Study 1). The second study was a 4-week, parallel-group at-home study in 295 patients (201 female and 94 male; median age 43 years) of 3.5 mg of Intermezzo compared to placebo, used on an as-needed basis after spontaneous middle-of-the-night awakenings (Study 2). In Study 2, patients took Intermezzo during the night on 62% of study nights.</p>
<p><a name="p2576122"></a>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in actual practice.</p>
<p><a name="p2579122"></a>Table 1 shows the incidence of adverse reactions reported in Study 2 that occurred in 2% or more of Intermezzo-treated (3.5 mg) patients in which the incidence was greater than the incidence in placebo-treated patients. For women and other patients taking the 1.75 mg dose in Study 1, the incidence of adverse reactions was similar to the incidence seen with 3.5 mg of Intermezzo in Table 1.</p>
<p><a name="p2582122"></a>The most commonly reported adverse reactions in all treatment groups were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>.</p>
<a name="t2585122"></a><table border="1" cellpadding="1" cellspacing="1" width="100%">
<caption><span>Table 1: Summary of Adverse Reactions (â‰¥ 2%) in Outpatient, Double-Blind, Parallel-Group, Placebo-Controlled Study (Study 2)</span></caption>
<colgroup>
<col width="60%">
<col align="center" width="20%">
<col align="center" width="20%">
</colgroup>
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule">MedDRA System Organ Class Preferred Term</th>
<th class="Botrule Lrule Rrule Toprule" align="center">
<span class="Bold"><span class="Emphasis">3.5 mg Intermezzo</span></span><br>(n=150)</th>
<th class="Botrule Lrule Rrule Toprule" align="center">
<span class="Bold"><span class="Emphasis">Placebo</span></span><br>(n=145)</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis">4%</span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis">2%</span></span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">1%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold"><span class="Emphasis">General Disorders and Administration Site Conditions</span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis">3%</span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis">0%</span></span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">1%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis">5%</span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis">3%</span></span></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">3%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2â€ƒâ€ƒPost Marketing Experience</h2>
<p class="First"><a name="p3882728"></a>The following adverse reactions, have been identified during post-approval use of intermezzo.  Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to establish a causal relationship to drug exposure.</p>
<ul class="Disc"><li><span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">Application site reactions</span> primarily in the subligual area, have been reported.  These <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">application site reactions</span> included oral <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>, and <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucosal inflammation</span>. </li></ul>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_7"></a><a name="section-7"></a><p></p>
<h1>7â€ƒâ€ƒDRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1â€ƒâ€ƒCNS-active Drugs</h2>
<p class="First"><a name="p3596122"></a>Co-administration of zolpidem with other CNS depressants increases the risk of <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> <span class="Italics"><span class="Emphasis">[see Warnings and Precautions <a href="#Section_5.1">(5.1)</a>]</span></span>. Zolpidem tartrate was evaluated in healthy volunteers in single-dose interaction studies for several CNS drugs.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.1.1"></a><a name="section-7.1.1"></a><p></p>
<h3><span class="Italics">Imipramine</span></h3>
<p class="First"><a name="p3614122"></a>Imipramine in combination with zolpidem produced no <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> other than a 20% decrease in peak levels of imipramine, but there was an additive effect of decreased alertness. Similarly, chlorpromazine in combination with zolpidem produced no <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span>, but there was an additive effect of decreased alertness and psychomotor performance.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.1.2"></a><a name="section-7.1.2"></a><p></p>
<h3><span class="Italics">Haloperidol</span></h3>
<p class="First"><a name="p3622122"></a>A study involving haloperidol and zolpidem revealed no effect of haloperidol on the pharmacokinetics or pharmacodynamics of zolpidem. The lack of a drug interaction following single-dose administration does not predict the absence of an effect following chronic administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.1.3"></a><a name="section-7.1.3"></a><p></p>
<h3><span class="Italics">Alcohol</span></h3>
<p class="First"><a name="p3630122"></a>An additive adverse effect on psychomotor performance between alcohol and oral zolpidem was demonstrated <span class="Italics"><span class="Emphasis">[see Warnings and Precautions <a href="#Section_5.1">(5.1)</a>]</span></span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.1.4"></a><a name="section-7.1.4"></a><p></p>
<h3><span class="Italics">Sertraline</span></h3>
<p class="First"><a name="p3854122"></a>Concomitant administration of zolpidem and sertraline increases exposure to zolpidem and may increase the pharmacodynamic effect of zolpidem.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.1.5"></a><a name="section-7.1.5"></a><p></p>
<h3><span class="Italics">Fluoxetine</span></h3>
<p class="First"><a name="p3862122"></a>After multiple doses of zolpidem tartrate and fluoxetine, an increase in the zolpidem half-life (17%) was observed. There was no evidence of an additive effect in psychomotor performance <span class="Italics"><span class="Emphasis">[see Clinical Pharmacology <a href="#Section_12.3">(12.3)</a>]</span></span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2â€ƒâ€ƒDrugs that Affect Drug Metabolism via Cytochrome P450</h2>
<p class="First"><a name="p3880122"></a>Some compounds known to inhibit CYP3A may increase exposure to zolpidem. The effect of other P450 enzymes on the exposure to zolpidem is not known.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.2.1"></a><a name="section-7.2.1"></a><p></p>
<h3><span class="Italics">Rifampin</span></h3>
<p class="First"><a name="p3888122"></a>Rifampin, a CYP3A4 inducer, significantly reduced the exposure to and the pharmacodynamic effects of zolpidem. Use of rifampin in combination with zolpidem may decrease the efficacy of zolpidem.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.2.2"></a><a name="section-7.2.2"></a><p></p>
<h3><span class="Italics">Ketoconazole</span></h3>
<p class="First"><a name="p4102122"></a>Ketoconazole, a potent CYP3A4 inhibitor, increased the pharmacodynamic effects of zolpidem. Consideration should be given to using a lower dose of zolpidem when ketoconazole and zolpidem are given together.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="Section_8"></a><a name="section-8"></a><p></p>
<h1>8â€ƒâ€ƒUSE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1â€ƒâ€ƒPregnancy</h2>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_8.1.1"></a><a name="section-8.1.1"></a><p></p>
<h3>Pregnancy Category C</h3>
<p class="First"><a name="p4136122"></a>There are no adequate and well-controlled studies of zolpidem in pregnant women. Studies in children to assess the effects of prenatal exposure to zolpidem have not been conducted; however, cases of severe <span class="product-label-link" type="condition" conceptid="4318857" conceptname="Neonatal respiratory depression">neonatal respiratory depression</span> have been reported when zolpidem was used at the end of pregnancy, especially when taken with other CNS-depressants. Children born to mothers taking sedative-hypnotic drugs may be at risk for withdrawal symptoms during the postnatal period. Neonatal <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">flaccidity</span> has also been reported in infants born to mothers who received sedative-hypnotic drugs during pregnancy. Intermezzo should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus.</p>
<p><a name="p4139122"></a>Administration of zolpidem to pregnant rats and rabbits resulted in adverse effects on offspring at doses greater than the recommended human dose (RHD) of 3.5 mg/day (approximately 2.8 mg/day zolpidem base); however, <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was not observed.</p>
<p><a name="p4144122"></a>When zolpidem was administered at oral doses of 4, 20, and 100 mg base/kg/day to pregnant rats during the period of organogenesis, dose-related decreases in fetal skull ossification were observed at all but the lowest dose, which is approximately 15 times the RHD on a mg/m<span class="Sup">2</span> basis. In rabbits treated during organogenesis with zolpidem at oral doses of 1, 4, and 16 mg base/kg/day, increased embryo-<span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span> and incomplete fetal skull ossification were seen at the highest dose tested. The no-effect dose for embryo-fetal toxicity in rabbits is approximately 30 times the RHD on a mg/m<span class="Sup">2</span> basis. Administration of zolpidem to rats at oral doses of 4, 20, and 100 mg base/kg/day during the latter part of pregnancy and throughout lactation produced decreased offspring growth and survival at all but the lowest dose, which is approximately 15 times the RHD on a mg/m<span class="Sup">2</span> basis.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="Section_8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3â€ƒâ€ƒNursing Mothers</h2>
<p class="First"><a name="p4370122"></a>Zolpidem is excreted in human milk. The effect of zolpidem on the nursing infant is not known.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Section_8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4â€ƒâ€ƒPediatric Use</h2>
<p class="First"><a name="p4378122"></a>Intermezzo is not recommended for use in children. Safety and effectiveness of Intermezzo have not been established in pediatric patients below the age of 18.</p>
<p><a name="p4381122"></a>In an 8-week study in pediatric patients (aged 6 to 17 years) with <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> associated with <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span>, an oral solution of zolpidem tartrate dosed at 0.25 mg/kg at bedtime did not decrease sleep latency compared to placebo. <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span> were reported in 7% of the pediatric patients who received zolpidem; none of the pediatric patients who received placebo reported <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Section_8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5â€ƒâ€ƒGeriatric Use</h2>
<p class="First"><a name="p4389122"></a>Intermezzo dosage adjustment is necessary in geriatric patients. Sedating drugs may cause <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and over-sedation in the elderly; elderly patients generally should be started on low doses of Intermezzo and observed closely <span class="Italics"><span class="Emphasis">[see Dosage and Administration <a href="#Section_2.4">(2.4)</a>, and Clinical Pharmacology <a href="#Section_12.3">(12.3)</a>]</span></span>.</p>
<p><a name="p4612122"></a><span class="Italics"><span class="Emphasis">Clinical trial experience with other zolpidem formulations (5 mg to 10 mg oral zolpidem tartrate) given at bedtime: </span></span></p>
<p><a name="p4619122"></a>A total of 154 patients in U.S.-controlled clinical trials and 897 patients in non-U.S. clinical trials who received oral zolpidem were â‰¥ 60 years of age. For a pool of U.S. patients receiving oral zolpidem tartrate at doses of â‰¤ 10 mg or placebo, there were three adverse reactions occurring at an incidence of at least 3% for zolpidem and for which the zolpidem incidence was at least twice the placebo incidence (see Table 2).</p>
<a name="t4622122"></a><table border="1" cellpadding="1" cellspacing="1" width="100%">
<caption><span>Table 2: Adverse Reactions in Geriatric Patients in Pooled Trials of 5 mg to 10 mg of Oral Zolpidem Tartrate Given at Bedtime</span></caption>
<colgroup>
<col align="center" width="30%">
<col align="center" width="40%">
<col align="center" width="30%">
</colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Adverse Reaction</td>
<td class="Botrule Lrule Rrule Toprule" align="center">5 to 10 mg Oral<br>Zolpidem tartrate</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Placebo</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">3%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">5%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">3%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1%</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="34082-8">
<a name="Section_8.5.1"></a><a name="section-8.4.1"></a><p></p>
<h3><span class="Italics"><span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">Falls</span> in geriatric patients:</span></h3>
<p class="First"><a name="p4891122"></a>A total of 30/1,959 (2%) non-U.S. patients receiving other zolpidem formulations (5 mg to 10 mg oral zolpidem tartrate) reported <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span>, including 28/30 (93%) who were â‰¥ 70 years of age. Of these 28 patients, 23 (82%) were receiving zolpidem tartrate doses &gt; 10 mg. A total of 24/1,959 (1%) non-U.S. patients receiving zolpidem reported <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, including 18/24 (75%) who were â‰¥70 years of age. Of these 18 patients, 14 (78%) were receiving zolpidem tartrate doses &gt;10 mg.</p>
<p><a name="p4894122"></a>The dose of Intermezzo in elderly patients is 1.75 mg to minimize adverse effects related to impaired motor and/or cognitive performance and unusual sensitivity to sedative-hypnotic drugs.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6â€ƒâ€ƒGender Difference in Pharmacokinetics</h2>
<p class="First"><a name="p4902122"></a>Women cleared zolpidem tartrate from the body after sublingual administration of a 3.5 mg dose of Intermezzo at a lower rate than men (2.7 mL/min/kg vs. 4.0 mL/min/kg). C<span class="Sub">max</span> and AUC parameters of zolpidem were approximately 45% higher at the same dose in female subjects compared with male subjects. Given the higher blood levels of zolpidem tartrate in women compared to men at a given dose, the recommended dose of Intermezzo for women is 1.75 mg, and the recommended dose for adult men is 3.5 mg.</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="Section_9"></a><a name="section-9"></a><p></p>
<h1>9â€ƒâ€ƒDRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="Section_9.1"></a><a name="section-9.1"></a><p></p>
<h2>9.1â€ƒâ€ƒControlled Substance</h2>
<p class="First"><a name="p5125122"></a>Zolpidem tartrate is classified as a Schedule IV controlled substance by federal regulation.</p>
</div>
<div class="Section" data-sectionCode="34086-9">
<a name="Section_9.2"></a><a name="section-9.2"></a><p></p>
<h2>9.2â€ƒâ€ƒAbuse</h2>
<p class="First"><a name="p5133122"></a>Abuse and addiction are separate and distinct from physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and tolerance. Abuse is characterized by misuse of the drug for non-medical purposes, often in combination with other psychoactive substances. Tolerance is a state of adaptation in which exposure to a drug induces changes that result in diminution of one or more of the drug effects over time. Tolerance may occur to both desired and undesired effects of drugs and may develop at different rates for different effects.</p>
<p><a name="p5136122"></a>Addiction is a primary, chronic, neurobiological disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. It is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving. <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug addiction</span> is a treatable disease, using a multidisciplinary approach, but relapse is common.</p>
<p><a name="p5139122"></a>Studies of abuse potential in former drug abusers found that the effects of single doses of 40 mg of oral zolpidem tartrate were similar, but not identical, to diazepam 20 mg, while 10 mg of oral zolpidem tartrate was difficult to distinguish from placebo.</p>
<p><a name="p5142122"></a>Because persons with a history of addiction to or abuse of drugs or alcohol are at increased risk for misuse, abuse and addiction of zolpidem, they should be monitored carefully when receiving Intermezzo.</p>
</div>
<div class="Section" data-sectionCode="34087-7">
<a name="Section_9.3"></a><a name="section-9.3"></a><p></p>
<h2>9.3â€ƒâ€ƒDependence</h2>
<p class="First"><a name="p5150122"></a>Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> is a state of adaptation that is manifested by a specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, decreasing blood level of the drug, and/or administration of an antagonist.</p>
<p><a name="p5153122"></a>Sedative-hypnotics have produced withdrawal signs and symptoms following abrupt discontinuation. These reported symptoms range from mild <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span> and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> to a withdrawal syndrome that may include abdominal and <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. The following adverse events which are considered to meet the DSM-III-R criteria for uncomplicated sedative-hypnotic withdrawal were reported during U.S. clinical trials with other oral zolpidem formulations following placebo substitution occurring within 48 hours following the last zolpidem treatment: <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, uncontrolled <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attack</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, and <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>. These reported adverse events occurred at an incidence of 1% or less. However, available data cannot provide a reliable estimate of the incidence, if any, of <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> during treatment at recommended doses. Post-marketing reports of abuse, <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, and withdrawal resulting from use of oral zolpidem tartrate have been received.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Section_10"></a><a name="section-10"></a><p></p>
<h1>10â€ƒâ€ƒOVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_10.1"></a><a name="section-10.1"></a><p></p>
<h2>10.1â€ƒâ€ƒSigns and Symptoms</h2>
<p class="First"><a name="p5166122"></a>In post-marketing experience of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with oral zolpidem tartrate alone, or in combination with CNS-depressant agents, impairment of consciousness ranging from <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> to <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, cardiovascular and/or respiratory compromise, and fatal outcomes have been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_10.2"></a><a name="section-10.2"></a><p></p>
<h2>10.2â€ƒâ€ƒRecommended Treatment</h2>
<p class="First"><a name="p5380122"></a>General symptomatic and supportive measures should be used along with immediate gastric lavage where appropriate. Intravenous fluids should be administered as needed. Zolpidemâ€™s sedative-hypnotic effect was shown to be reduced by flumazenil and therefore flumazenil may be useful; however, flumazenil administration may contribute to the appearance of neurological symptoms (<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>). As in all cases of drug <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, respiration, pulse, blood pressure, and other appropriate signs should be monitored and general supportive measures employed. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> and <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> should be treated by appropriate medical intervention. Sedating drugs should be withheld following zolpidem overdosage, even if excitation occurs. The value of dialysis in the treatment of overdosage has not been determined, although hemodialysis studies in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> receiving therapeutic doses have demonstrated that zolpidem is not dialyzable.</p>
<p><a name="p5383122"></a>As with management of all overdosage, the possibility of multiple drug ingestion should be considered. The healthcare provider may wish to consider contacting a poison control center for up-to-date information on the management of hypnotic drug overdosage.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Section_11"></a><a name="section-11"></a><p></p>
<h1>11â€ƒâ€ƒDESCRIPTION</h1>
<p class="First"><a name="p5391122"></a>Intermezzo contains zolpidem tartrate, a non-benzodiazepine hypnotic of the imidazopyridine class. Intermezzo is available in 1.75 mg and 3.5 mg strength tablets for sublingual administration. Intermezzo sublingual tablets are intended to be placed under the tongue where they will disintegrate.</p>
<p><a name="p5394122"></a>Intermezzo sublingual tablets contain a <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>-carbonate buffer.</p>
<p><a name="p5397122"></a>Chemically, zolpidem tartrate is <span class="Italics">N</span>,<span class="Italics">N</span>-6-trimethyl-2-<span class="Italics">p</span>-tolylimidazo[1,2-Î±]pyridine-3-acetamide L-(+)-tartrate (2:1).</p>
<div class="Figure"><img alt="Intermezzo structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=913b6cfe-1fb0-44a8-817a-26374bbce995&amp;name=intermezzo-struct.jpg"></div>
<p><a name="p5420122"></a>Zolpidem tartrate is a white to off-white crystalline powder that is sparingly soluble in water, alcohol, and propylene glycol. It has a molecular weight of 764.88.</p>
<p><a name="p5423122"></a>Each Intermezzo tablet includes the following inactive ingredients: mannitol, sorbitol, crospovidone, silicon dioxide, sodium carbonate, sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>, croscarmellose sodium, sodium stearyl fumarate, silicon dioxide, natural and artificial spearmint flavor, silicon dioxide-colloidal, and sucralose. The 1.75 mg tablet also contains yellow iron oxide, and the 3.5 mg tablet contains beige iron oxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Section_12"></a><a name="section-12"></a><p></p>
<h1>12â€ƒâ€ƒCLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="Section_12.1"></a><a name="section-12.1"></a><p></p>
<h2>12.1â€ƒâ€ƒMechanism of Action</h2>
<p class="First"><a name="p5642122"></a>Zolpidem, the active moiety of zolpidem tartrate, is a hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties. It interacts with a GABA-BZ complex and shares some of the pharmacological properties of the benzodiazepines. In contrast to the benzodiazepines, which nonselectively bind to and activate all BZ receptor subtypes, zolpidem <span class="Italics">in vitro</span> binds the BZ<span class="Sub">1</span> receptor preferentially with a high affinity ratio of the alpha<span class="Sub">1</span>/alpha<span class="Sub">5</span> subunits. This selective binding of zolpidem on the BZ<span class="Sub">1</span> receptor is not absolute, but it may explain the relative absence of myorelaxant and anticonvulsant effects in animal studies as well as the preservation of deep sleep (stages 3 and 4) in human studies of zolpidem at hypnotic doses.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="Section_12.3"></a><a name="section-12.2"></a><p></p>
<h2>12.3â€ƒâ€ƒPharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.1"></a><a name="section-12.2.1"></a><p></p>
<h3><span class="Italics">Absorption</span></h3>
<p class="First"><a name="p5675122"></a>Intermezzo disintegrates in the sublingual cavity after administration. On average, Intermezzo is rapidly absorbed in both genders, with a mean T<span class="Sub">max</span> across studies of about 35 minutes to about 75 minutes.</p>
<p><a name="p5888122"></a>In healthy normal volunteers (age 21 to 45 years) dosed with 3.5 mg Intermezzo, the average C<span class="Sub">max</span> and AUC were 77 ng/mL and 296 ngâ€¢h/mL, respectively in women. The average C<span class="Sub">max</span> and AUC were 53 ng/mL and 198 ngâ€¢h/mL, respectively in men. In women, the average C<span class="Sub">max</span> and AUC of the 1.75 mg Intermezzo dose were 37 ng/mL and 151 ngâ€¢h/mL, respectively.</p>
<p><a name="p5903122"></a>Food decreased the overall C<span class="Sub">max</span> and AUC of Intermezzo 3.5 mg by 42% and 19%, respectively, and increased the time to peak exposure (T<span class="Sub">max</span>) to nearly 3 hours. For optimal effect, Intermezzo should not be administered with or immediately after a meal.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.2"></a><a name="section-12.2.2"></a><p></p>
<h3><span class="Italics">Distribution</span></h3>
<p class="First"><a name="p5919122"></a>Based on data obtained with oral zolpidem, the total protein binding was found to be 93% Â± 0.1% and remained constant independent of concentration between 40 ng/mL and 790 ng/mL.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.3"></a><a name="section-12.2.3"></a><p></p>
<h3><span class="Italics">Metabolism</span></h3>
<p class="First"><a name="p5927122"></a>Based on data obtained with oral zolpidem, zolpidem tartrate is converted to inactive metabolites that are eliminated primarily by renal excretion.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.4"></a><a name="section-12.2.4"></a><p></p>
<h3><span class="Italics">Elimination</span></h3>
<p class="First"><a name="p5935122"></a>The elimination half-life of a single dose of a 3.5 mg Intermezzo sublingual tablet is approximately 2.5 hours (range 1.4 to 3.6 hours).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.4"></a><a name="section-12.3"></a><p></p>
<h2></h2>
<p class="First"><a name="p6148122"></a><span class="Bold"><span class="Emphasis">Special Populations</span></span></p>
<p><a name="p6155122"></a><span class="Italics"><span class="Emphasis">Elderly</span></span>: The recommended dose for Intermezzo is 1.75 mg. A pharmacokinetic study of 1.75 mg and 3.5 mg doses of Intermezzo showed that the plasma C<span class="Sub">max</span> and AUC<span class="Sub">0-4 hr</span> in elderly subjects following the 3.5 mg dose was higher by 34% and 30%, respectively, than the non-elderly subjects. The C<span class="Sub">max</span> and AUC of 1.75 mg in elderly subjects were consistently lower than those observed for the 3.5 mg dose in non-elderly subjects but consistently higher than the 1.75 mg dose in non-elderly subjects. The elimination half-life remained unchanged.</p>
<p><a name="p6171122"></a><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></span>: The pharmacokinetics of oral zolpidem tartrate in eight patients with chronic <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> were compared to results in subjects with normal hepatic function. Following a single 20 mg oral zolpidem tartrate dose, mean C<span class="Sub">max</span> and AUC were found to be two times (250 ng/mL vs. 499 ng/mL) and five times (788 ngâ€¢hr/mL vs. 4203 ngâ€¢hr/mL) higher, respectively, in hepatically compromised patients compared to subjects with normal hepatic function. T<span class="Sub">max</span> did not change. The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in subjects with normal hepatic function of 2.2 hr (range: 1.6 to 2.4 hr). Dosing should be modified accordingly in patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> <span class="Italics"><span class="Emphasis">[see Dosage and Administration <a href="#Section_2.5">(2.5)</a>]</span></span>.</p>
<p><a name="p6403122"></a><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></span>: The pharmacokinetics of zolpidem tartrate were studied in  11 patients with end-stage <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> (mean Cl<span class="Sub">Cr</span>= 6.5 Â± 1.5 mL/min) undergoing hemodialysis three times a week, who were dosed with zolpidem tartrate 10 mg orally each day for 14 or 21 days. No statistically significant differences were observed for C<span class="Sub">max</span>, T<span class="Sub">max</span>, half-life, and AUC between the first and last day of drug administration when baseline concentration adjustments were made. Zolpidem was not hemodialyzable. No accumulation of unchanged drug appeared after 14 or 21 days. Zolpidem pharmacokinetics were not significantly different in renally-impaired patients. No dosage adjustment is necessary in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.5"></a><a name="section-12.4"></a><p></p>
<h2></h2>
<p class="First"><a name="p6427122"></a><span class="Bold"><span class="Emphasis">Drug Interactions</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.5.1"></a><a name="section-12.4.1"></a><p></p>
<h3><span class="Italics">CNS-depressants</span></h3>
<p class="First"><a name="p6439122"></a>Co-administration of zolpidem with other CNS depressants increases the risk of <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> <span class="Italics"><span class="Emphasis">[see Warnings and Precautions <a href="#Section_5.1">(5.1)</a>]</span></span>. Zolpidem tartrate was evaluated in healthy volunteers in single-dose interaction studies for several CNS drugs. Imipramine in combination with zolpidem produced no <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> other than a 20% decrease in peak levels of imipramine, but there was an additive effect of decreased alertness. Similarly, chlorpromazine in combination with zolpidem produced no <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span>, but there was an additive effect of decreased alertness and psychomotor performance.</p>
<p><a name="p6658122"></a>A study involving haloperidol and zolpidem revealed no effect of haloperidol on the pharmacokinetics or pharmacodynamics of zolpidem. The lack of a drug interaction following single-dose administration does not predict the absence of an effect following chronic administration.</p>
<p><a name="p6661122"></a>An additive adverse effect on psychomotor performance between alcohol and oral zolpidem was demonstrated <span class="Italics"><span class="Emphasis">[see Warnings and Precautions <a href="#Section_5.1">(5.1)</a>]</span></span>.</p>
<p><a name="p6674122"></a>Following five consecutive nightly doses at bedtime of oral zolpidem tartrate 10 mg in the presence of sertraline 50 mg (17 consecutive daily doses, at 7:00 am, in healthy female volunteers), zolpidem C<span class="Sub">max</span> was significantly higher (43%) and T<span class="Sub">max</span> was significantly decreased (-53%). Pharmacokinetics of sertraline and N-desmethylsertraline were unaffected by zolpidem.</p>
<p><a name="p6685122"></a>A single-dose interaction study with zolpidem tartrate 10 mg and fluoxetine 20 mg at steady-state levels in male volunteers did not demonstrate any clinically significant pharmacokinetic or <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacodynamic interactions</span>. When multiple doses of zolpidem and fluoxetine were given at steady state and the concentrations evaluated in healthy females, an increase in the zolpidem half-life (17%) was observed. There was no evidence of an additive effect in psychomotor performance.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.5.2"></a><a name="section-12.4.2"></a><p></p>
<h3><span class="Italics">Drugs that Affect Drug Metabolism via Cytochrome P450</span></h3>
<p class="First"><a name="p6693122"></a>Some compounds known to inhibit CYP3A may increase exposure to zolpidem. The effect of inhibitors of other P450 enzymes on the pharmacokinetics of zolpidem is unknown.</p>
<p><a name="p6696122"></a>A single-dose interaction study with zolpidem tartrate 10 mg and itraconazole 200 mg at steady-state levels in male volunteers resulted in a 34% increase in AUC<span class="Sub">0-âˆž</span> of zolpidem tartrate. There were no pharmacodynamic effects of zolpidem detected on subjective <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, postural sway, or psychomotor performance.</p>
<p><a name="p6703122"></a>A single-dose interaction study with zolpidem tartrate 10 mg and rifampin 600 mg at steady-state levels in female subjects showed significant reductions of the AUC (-73%), C<span class="Sub">max</span> (-58%), and T<span class="Sub">1/2</span> (-36 %) of zolpidem together with significant reductions in the pharmacodynamic effects of zolpidem tartrate. Rifampin, a CYP3A4 inducer, significantly reduced the exposure to and the pharmacodynamic effects of zolpidem.</p>
<p><a name="p6920122"></a>A single-dose interaction study with zolpidem tartrate 5 mg and ketoconazole, a potent CYP3A4 inhibitor, given as 200 mg twice daily for 2 days increased C<span class="Sub">max</span> of zolpidem (30%) and the total AUC of zolpidem (70%) compared to zolpidem alone and prolonged the elimination half-life (30%) along with an increase in the pharmacodynamic effects of zolpidem. Consideration should be given to using a lower dose of zolpidem when ketoconazole and zolpidem are given together.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.5.3"></a><a name="section-12.4.3"></a><p></p>
<h3><span class="Italics">Other Drugs with No Interactions with Zolpidem</span></h3>
<p class="First"><a name="p6932122"></a>A study involving cimetidine/zolpidem tartrate and ranitidine/zolpidem tartrate combinations revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of zolpidem.</p>
<p><a name="p6935122"></a>Zolpidem tartrate had no effect on digoxin pharmacokinetics and did not affect <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time when given with warfarin in healthy subjects.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="Section_13"></a><a name="section-13"></a><p></p>
<h1>13â€ƒâ€ƒNONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_13.1"></a><a name="section-13.1"></a><p></p>
<h2>13.1â€ƒâ€ƒCarcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><a name="p6948122"></a><span class="Italics">Carcinogenesis:</span> Zolpidem was administered in the diet to rats and mice for 2 years at doses of 4, 18, and 80 mg base/kg/day. In mice, these doses are approximately 7, 30, and 140 times, respectively, the recommended human dose (RHD) of 3.5 mg/day (approximately 2.8 mg zolpidem base) on a mg/m<span class="Sup">2</span> basis. In rats, these doses are approximately 15, 60, and 280 times, respectively, the RHD on a mg/m<span class="Sup">2</span> basis. No evidence of carcinogenic potential was observed in mice. In rats, renal tumors (<span class="product-label-link" type="condition" conceptid="440358" conceptname="Lipoma">lipoma</span>, liposarcoma) were seen at the mid- and high doses.</p>
<p><a name="p6959122"></a><span class="Italics">Mutagenesis:</span> Zolpidem was negative in <span class="Italics">in vitro</span> (bacterial reverse mutation, mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, and chromosomal aberration) and <span class="Italics">in vivo</span> (mouse micronucleus) genetic toxicology assays.</p>
<p><a name="p7176122"></a><span class="Italics">Impairment of fertility:</span> Oral administration of zolpidem (doses of 4, 20, and 100 mg base/kg/day) to rats prior to and during mating, and continuing in females through postpartum day 25, resulted in irregular estrus cycles and prolonged precoital intervals at the highest dose tested. The no-effect dose for these findings is approximately 70 times the RHD on a mg/m<span class="Sup">2</span> basis. There was no impairment of fertility at any dose tested.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="Section_14"></a><a name="section-14"></a><p></p>
<h1>14â€ƒâ€ƒCLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.1"></a><a name="section-14.1"></a><p></p>
<h2>14.1â€ƒâ€ƒMiddle-of-the-Night Awakening Trials</h2>
<p class="First"><a name="p7193122"></a>Intermezzo was evaluated in two randomized, double-blind, placebo-controlled studies (Studies 1 and 2) in patients with <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> characterized by difficulty returning to sleep after a middle-of-the-night (MOTN) awakening. In these studies, patients met the diagnosis for primary <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> as defined by the Diagnostic and Statistical Manual of <span class="product-label-link" type="condition" conceptid="432586" conceptname="Mental disorder">Mental Disorders</span> (DSM-IV-TR) and had at least three prolonged MOTN awakenings per week that were at least 30 minutes in duration.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.1.1"></a><a name="section-14.1.1"></a><p></p>
<h3><span class="Italics">Sleep Laboratory Study (Scheduled Dosing)</span></h3>
<p class="First"><a name="p7201122"></a>Adult patients aged 19 to 64 years (N=82; 58 female, 24 male) with a history of difficulty returning to sleep after middle-of-the-night awakenings were evaluated in a double-blind, placebo-controlled, 3-period cross-over sleep laboratory study (Study 1). The primary outcome measure was latency to persistent sleep (LPS).</p>
<p><a name="p7204122"></a>Doses of 3.5 mg and 1.75 mg of Intermezzo significantly decreased both objective (by polysomnography) and subjective (patient-estimated) sleep latency after a scheduled middle-of-the-night awakening as compared to placebo. The effect on sleep latency was similar for females receiving 1.75 mg of Intermezzo and males receiving 3.5 mg of Intermezzo.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.1.2"></a><a name="section-14.1.2"></a><p></p>
<h3><span class="Italics">Outpatient Study (As-needed Dosing)</span></h3>
<p class="First"><a name="p7212122"></a>Adult patients aged 18 to 64 years (N=295; 201 women, 94 men) with difficulty returning to sleep after middle-of-the-night awakenings were evaluated in a double-blind, placebo-controlled 4-week outpatient study of Intermezzo. Patients took study drug (3.5 mg of Intermezzo or placebo) on an as-needed (prn) basis, when they had difficulty returning to sleep after waking in the middle of the night, provided they had at least 4 hours time remaining in bed. Subjective (patient-estimated) time to <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> back to sleep after middle-of-the-night awakening was significantly shorter for Intermezzo 3.5 mg compared to placebo.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.2"></a><a name="section-14.2"></a><p></p>
<h2>14.2â€ƒâ€ƒSpecial Safety Studies</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.2.1"></a><a name="section-14.2.1"></a><p></p>
<h3><span class="Italics">Driving Study</span></h3>
<p class="First"><a name="p7431122"></a>A randomized, double-blind, placebo-controlled, active-control, single-center, four-period, crossover study in 40 healthy subjects was conducted to evaluate the effects of middle-of-the-night administration of Intermezzo on next-morning driving performance. The four randomized treatments included Intermezzo 3.5 mg four hours before driving, Intermezzo 3.5 mg three hours before driving, placebo, and a positive control (an unapproved sedative-hypnotic) given nine hours before driving.</p>
<p><a name="p7437122"></a>The primary outcome measure was the change in the standard deviation of lateral position (SDLP), a measure of driving impairment. The results were analyzed using a symmetry analysis, which determined the proportion of subjects whose change from their own SDLP in the placebo condition was statistically significantly above a threshold thought to reflect clinically meaningful driving impairment.</p>
<p><a name="p7440122"></a>When driving began 3 hours after taking Intermezzo, testing had to be terminated for one subject (a 23-year old woman) due to <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>. Overall, the symmetry analysis showed a statistically significant impairing effect at 3 hours. When driving began 4 hours after taking Intermezzo, statistically significant impairment was not found, but numerically Intermezzo was worse than placebo. Zolpidem blood levels were not measured in the driving study, and the study was not designed to correlate specific blood level with degree of impairment. However, the estimated blood level of zolpidem in patients whose SDLP worsened according to the symmetry analysis is considered to present a risk for driving impairment. In some women, the 3.5 mg dose of Intermezzo results in zolpidem blood levels that remain at or sometimes considerably above this level 4 or more hours after dosing. Therefore, the recommended dose for women is 1.75 mg. A small negative effect on SDLP may remain in some patients 4 hours after the 1.75 mg dose in women, and after the 3.5 mg dose in men, such that a potential negative effect on driving cannot be completely excluded.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.2.2"></a><a name="section-14.2.2"></a><p></p>
<h3><span class="Italics">Rebound effects</span></h3>
<p class="First"><a name="p7449122"></a>In studies performed with other zolpidem formulations (5 mg to 10 mg oral zolpidem tartrate) given at bedtime, there was no objective (polysomnographic) evidence of rebound <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> at recommended doses seen in studies evaluating sleep on the nights following discontinuation. There was subjective evidence of impaired sleep in the elderly on the first post-treatment night at doses above the recommended elderly dose of 5 mg oral zolpidem tartrate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.2.3"></a><a name="section-14.2.3"></a><p></p>
<h3><span class="Italics"><span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">Memory impairment</span> in controlled studies</span></h3>
<p class="First"><a name="p7457122"></a>Controlled studies in adults utilizing objective measures of memory yielded no consistent evidence of next-day <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span> following the administration at bedtime of 5 mg to 10 mg oral zolpidem tartrate. However, in one study involving zolpidem tartrate doses of 10 mg and 20 mg, there was a significant decrease in next-morning recall of information presented to subjects during peak drug effect (90 minutes post-dose), i.e., these subjects experienced <span class="product-label-link" type="condition" conceptid="4229448" conceptname="Anterograde amnesia">anterograde amnesia</span>. There was also subjective evidence from adverse event data for <span class="product-label-link" type="condition" conceptid="4229448" conceptname="Anterograde amnesia">anterograde amnesia</span> occurring in association with the administration of oral zolpidem tartrate, predominantly at doses above 10 mg.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_16"></a><a name="section-15"></a><p></p>
<h1>16â€ƒâ€ƒHOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"><a name="p7465122"></a>Each sublingual tablet is individually packaged in a unit-dose pouch.</p>
<p><a name="p7468122"></a>Intermezzo 1.75 mg tablets are yellow, round, uncoated, biconvex, debossed with ZZ on one side and supplied as:</p>
<p><a name="p7471122"></a><span class="Bold">NDC</span> 59011-256-30: Carton of 30 unit-dose pouches</p>
<p><a name="p7683122"></a>Intermezzo 3.5 mg tablets are beige, round, uncoated, biconvex, debossed with ZZ on one side and supplied as:</p>
<p><a name="p7686122"></a><span class="Bold">NDC</span> 59011-255-30: Carton of 30 unit-dose pouches</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_16.1"></a><a name="section-15.1"></a><p></p>
<p class="First"><a name="p7694122"></a><span class="Italics"><span class="Emphasis">Storage and Handling</span></span></p>
<p><a name="p7701122"></a>Store between 20Â°C to 25Â°C (68Â°F to 77Â°F). Excursions permitted between 15Â°C and 30Â°C (59Â°F and 86Â°F). Protect from moisture.</p>
<p><a name="p7704122"></a>The patient should be instructed not to remove the sublingual tablet from the unit-dose pouch until the patient is ready to consume it.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Section_17"></a><a name="section-16"></a><p></p>
<h1>17â€ƒâ€ƒPATIENT COUNSELING INFORMATION</h1>
<p class="First"><a name="p7712122"></a><span class="Italics"><span class="Emphasis">See FDA-approved patient labeling (Medication Guide).</span></span></p>
<p><a name="p7719122"></a>Inform patients and their families about the benefits and risks of treatment with Intermezzo. Inform patients of the availability of a Medication Guide and instruct them to read the Medication Guide prior to initiating treatment with Intermezzo and with each prescription refill. Review the Intermezzo Medication Guide with every patient prior to initiation of treatment. Instruct patients or caregivers that Intermezzo should be taken only as prescribed.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.1"></a><a name="section-16.1"></a><p></p>
<h2></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.1.1"></a><a name="section-16.1.1"></a><p></p>
<h3><span class="Underline"><span class="Italics">CNS depressant Effects and Next-Day Impairment</span></span></h3>
<p class="First"><a name="p7937122"></a>Tell patients that Intermezzo has the potential to cause next-day impairment, and that this risk is increased if dosing instructions are not carefully followed. Tell patients to wait for at least 4 hours after dosing and until they feel fully awake before driving or engaging in other activities requiring full mental alertness.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.1.2"></a><a name="section-16.1.2"></a><p></p>
<h3><span class="Underline"><span class="Italics">Severe Anaphylactic and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></span></span></h3>
<p class="First"><a name="p7945122"></a>Inform patients that severe anaphylactic and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> have occurred with zolpidem. Describe the signs/symptoms of these reactions and advise patients to seek medical attention immediately if any of them occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.1.3"></a><a name="section-16.1.3"></a><p></p>
<h3><span class="Italics"><span class="Underline">Sleep-driving and Other Complex Behaviors</span></span></h3>
<p class="First"><a name="p7953122"></a>Instruct patients to inform their families that zolpidem has been associated with â€œsleep-drivingâ€? and other complex behaviors while not being fully awake (preparing and eating food, making phone calls, or having sex), and tell patients and their families to call their healthcare providers immediately if they develop any of these symptoms.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.1.4"></a><a name="section-16.1.4"></a><p></p>
<h3><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span></span></span></h3>
<p class="First"><a name="p7961122"></a>Tell patients to immediately report any suicidal thoughts.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.1.5"></a><a name="section-16.1.5"></a><p></p>
<h3><span class="Italics"><span class="Underline">Administration Instructions</span></span></h3>
<p class="First"><a name="p7969122"></a>For detailed instructions on how to use Intermezzo, tell patients to refer to the Patient Instructions for Use.</p>
<p><a name="p7972122"></a>Tell patients that Intermezzo is to be taken only once per night if needed if they wake in the middle of the night and have difficulty returning to sleep. Tell patients that Intermezzo should only be taken if they have 4 hours of bedtime remaining before the planned time of waking.</p>
<p><a name="p7975122"></a>Instruct the patient to place the tablet under the tongue, allowing it to disintegrate completely before swallowing. Tell the patient that Intermezzo should not be swallowed whole.</p>
<p><a name="p7978122"></a>Tell patients that the effect of Intermezzo may be slowed if taken with or immediately after a meal.</p>
<p><a name="p7981122"></a>Instruct patients to remove the tablet from the unit-dose pouch just prior to dosing.</p>
<p><a name="p7984122"></a>Advise patients NOT to take Intermezzo if they drank alcohol that day or before bed.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.2"></a><a name="section-16.2"></a><p></p>
<h2></h2>
<p class="First"><a name="p8197122"></a>Healthcare professionals can telephone Purdue Pharmaâ€™s Medical Services Department (1-888-726-7535) for information on this product.</p>
<p><a name="p8200122"></a></p>
<p><a name="p8203122"></a>Distributed by:<br>Purdue Pharma L.P.,<br>Stamford, CT 06901-3431<br>Manufactured by: Patheon Pharmaceuticals, Inc., Cincinnati, OH 45237</p>
<p><a name="p21766222"></a>U.S. Patent Numbers 7658945; 7682628; 8,242,131; 8,252,809</p>
<p><a name="p8210122"></a>Â©2015, Purdue Pharma L.P.</p>
<br><br><br>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="Section_18"></a><a name="section-17"></a><p></p>
<h1></h1>
<p class="First"><a name="p8217122"></a><span class="Bold"><span class="Emphasis">MEDICATION GUIDE</span></span></p>
<p><a name="p8224122"></a><span class="Bold"><span class="Emphasis">Intermezzo<span class="Sup">Â®</span> (in ter mÃ©t zoh) </span></span></p>
<p><a name="p8235122"></a><span class="Bold"><span class="Emphasis">(zolpidem tartrate) sublingual tablet CIV</span></span></p>
<p><a name="p8448122"></a>Read the Medication Guide that comes with Intermezzo<span class="Sup">Â®</span> before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your doctor about your medical condition or treatment.</p>
<p><a name="p8455122"></a><span class="Bold"><span class="Emphasis">What is the most important information I should know about Intermezzo?</span></span></p>
<p><a name="p8462122"></a><span class="Bold"><span class="Emphasis">Follow the Instructions for Use at the end of this Medication Guide when you take Intermezzo. If you do not follow the Instructions for Use, you might be drowsy in the morning without knowing it.</span></span></p>
<ul class="Disc">
<li><span class="Bold"><span class="Emphasis">Only take one tablet a night, if needed. </span></span></li>
<li><span class="Bold"><span class="Emphasis">Only take Intermezzo if you have at least 4 hours of bedtime left.</span></span></li>
</ul>
<p><a name="p8485122"></a><span class="Bold"><span class="Emphasis">Intermezzo may cause serious side effects, including:</span></span></p>
<ul class="Disc"><li>
<span class="Bold"><span class="Emphasis">After taking Intermezzo, you may get up out of bed while not being fully awake and do an activity that you do not know you are doing. The next morning, you may not remember that you did anything during the night.</span></span> You have a higher chance for doing these activities if you drank alcohol that day or take other medicines that make you <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span> with Intermezzo. Reported activities include:	<ul class="Circle">
<li>driving a car ("sleep-driving")</li>
<li>making and eating food</li>
<li>talking on the phone</li>
<li>having sex</li>
<li>sleep-walking</li>
</ul>
</li></ul>
<p><a name="p8725122"></a><span class="Bold"><span class="Emphasis">Call your healthcare provider right away if you find out that you have done any of the above activities after taking Intermezzo.</span></span></p>
<p><a name="p8732122"></a><span class="Bold"><span class="Emphasis">Important:</span></span></p>
<ol class="Arabic">
<li><span class="Bold"><span class="Emphasis">Take Intermezzo exactly as prescribed</span></span></li>
<li>
<span class="Bold"><span class="Emphasis">Do not take Intermezzo if you:</span></span><ul class="Disc">
<li>drank alcohol that day or before bed.</li>
<li>took another medicine to help you sleep.</li>
<li>do not have at least 4 hours of bedtime remaining.</li>
</ul>
</li>
</ol>
<p><a name="p8972122"></a><span class="Bold"><span class="Emphasis">What is Intermezzo?</span></span></p>
<p><a name="p8979122"></a>Intermezzo is a sedative-hypnotic (sleep) medicine. Intermezzo is used in adults for the treatment of a <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep problem</span> called <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>. Many people have difficulty returning to sleep after awakening in the middle of the night. Intermezzo is designed to specifically treat this problem.</p>
<p><a name="p8982122"></a>It is not known if Intermezzo is safe and effective in children.</p>
<p><a name="p8985122"></a>Intermezzo is a federally controlled substance (CIV) because it can be abused or lead to <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. Keep Intermezzo in a safe place to prevent misuse and abuse. Selling or giving away Intermezzo may harm others, and is against the law. Tell your doctor if you have ever abused or have been dependent on alcohol, prescription medicines, or street drugs.</p>
<p><a name="p8988122"></a><span class="Bold"><span class="Emphasis">Who should not take Intermezzo?</span></span></p>
<ul class="Disc">
<li>Do not take Intermezzo if you are allergic to zolpidem or any other ingredients in Intermezzo. See the end of this Medication Guide for a complete list of ingredients in Intermezzo.</li>
<li>Do not take Intermezzo if you have had an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to drugs containing zolpidem, such as Ambien, Ambien CR, Edluar, or Zolpimist. </li>
</ul>
<p><a name="p9003122"></a><span class="Bold"><span class="Emphasis">Symptoms of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to Intermezzo can include:</span></span></p>
<ul class="Disc">
<li><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face, lips, and throat that may cause <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span> or swallowing</span></span></li>
<li><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></span></span></li>
</ul>
<p><a name="p9232122"></a><span class="Bold"><span class="Emphasis">Intermezzo may not be right for you. Before starting Intermezzo, tell your doctor about all of your health conditions, including if you:</span></span></p>
<ul class="Disc">
<li>have a history of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, mental illness, or suicidal thoughts</li>
<li>have a history of drug or <span class="product-label-link" type="condition" conceptid="433753" conceptname="Alcohol abuse">alcohol abuse</span> or addiction</li>
<li>have kidney or liver disease</li>
<li>have a <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span> or breathing problems</li>
<li>are pregnant, planning to become pregnant, or breastfeeding</li>
</ul>
<p><a name="p9256122"></a>Tell your doctor about all of the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements. Medicines can interact with each other, sometimes causing serious side effects. Your doctor will tell you if you can take Intermezzo with your other medicines.</p>
<p><a name="p9259122"></a>Know the medicines you take. Keep a list of your medicines with you to show your doctor and pharmacist each time you get a new medicine.</p>
<p><a name="p9262122"></a><span class="Bold"><span class="Emphasis">How should I take Intermezzo? </span></span></p>
<ul class="Disc">
<li>See <span class="Bold"><span class="Emphasis">â€œWhat is the most important information I should know about Intermezzoâ€? </span></span>
</li>
<li>Read the <span class="Bold"><span class="Emphasis">"Instructions for Use"</span></span> at the end of this Medication Guide for detailed instructions on how to take Intermezzo.</li>
<li>Take Intermezzo exactly as prescribed. Only take one Intermezzo tablet per night if needed.</li>
<li>Do not take Intermezzo if you drank alcohol that evening or before bed.</li>
<li>While in bed, place the tablet under your tongue and allow it to break apart completely. Do not swallow it whole.</li>
<li>You should not take Intermezzo with or right after a meal. Intermezzo may help you <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> asleep faster when you take it on an empty stomach.</li>
<li>Call your health care provider if your <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> worsens or is not better within 7 to 10 days. This may mean that there is another condition causing your <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep problem</span>.</li>
<li>If you take too much Intermezzo or <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, get emergency treatment.</li>
</ul>
<p><a name="p9512122"></a><span class="Bold"><span class="Emphasis">What are the possible side effects of Intermezzo?</span></span></p>
<p><a name="p9519122"></a>Intermezzo may cause serious side effects, including:</p>
<ul class="Disc">
<li>
<span class="Bold"><span class="Emphasis">getting out of bed while not being fully awake and doing an activity that you do not know you are doing.</span></span> (See <span class="Bold">â€œWhat is the most important information I should know about Intermezzo?â€?</span>)</li>
<li>
<span class="Bold"><span class="Emphasis">abnormal thoughts and behavior.</span></span> Symptoms include more outgoing or <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span> than normal, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and suicidal thoughts or actions.</li>
<li><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span></span></span></li>
<li><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span></span></span></li>
<li>
<span class="Bold"><span class="Emphasis">severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.</span></span> Symptoms include <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the tongue or throat, trouble breathing, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Get emergency medical help if you get these symptoms after taking Intermezzo.</li>
</ul>
<p><a name="p9768122"></a><span class="Bold"><span class="Emphasis">Call your health care provider right away if you have any of the above side effects or any other side effects that <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">worry</span> you while using Intermezzo.</span></span></p>
<p><a name="p9775122"></a><span class="Bold"><span class="Emphasis">The most common side effects of Intermezzo are:</span></span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></li>
</ul>
<p><a name="p9999122"></a>Even if you follow the Instructions for Use, you may still feel drowsy in the morning after taking Intermezzo. Do not drive or do other dangerous activities after taking Intermezzo until you are fully awake.</p>
<p><a name="p10002122"></a>These are not all the side effects of Intermezzo. Ask your health care provider or pharmacist for more information.</p>
<p><a name="p10005122"></a>You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><a name="p10008122"></a><span class="Bold"><span class="Emphasis">How should I store Intermezzo?</span></span></p>
<ul class="Disc">
<li>Store Intermezzo at room temperature, 68Â° to 77Â°F (20Â° to 25Â°C). Protect from moisture. </li>
<li>Only open the pouch when you are ready to use Intermezzo.</li>
</ul>
<p><a name="p10023122"></a><span class="Bold"><span class="Emphasis">Keep Intermezzo and all medicines out of reach of children.</span></span></p>
<p><a name="p10030122"></a><span class="Bold"><span class="Emphasis">General Information about Intermezzo</span></span></p>
<p><a name="p10243122"></a>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Intermezzo for a condition for which it was not prescribed. Do not give Intermezzo to other people, even if you think they have the same symptoms that you have. It may harm them and it is against the law.</p>
<p><a name="p10246122"></a>This Medication Guide summarizes the most important information about Intermezzo. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about Intermezzo that is written for healthcare professionals. For more information about Intermezzo, call Purdue Pharma at 1-888-726-7535 or go to www.purduepharma.com or www.intermezzorx.com.</p>
<p><a name="p10249122"></a></p>
<p><a name="p10251122"></a><span class="Bold"><span class="Emphasis">What are the ingredients in Intermezzo?</span></span></p>
<p><a name="p10258122"></a><span class="Bold"><span class="Emphasis">Active Ingredient: </span></span>Zolpidem tartrate</p>
<p><a name="p10266122"></a><span class="Bold"><span class="Emphasis">Inactive Ingredients: </span></span>Each Intermezzo tablet includes the following inactive ingredients: mannitol, sorbitol, crospovidone, silicon dioxide, sodium carbonate, sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>, croscarmellose sodium, sodium stearyl fumarate, silicon dioxide, natural and artificial spearmint flavor, silicon dioxide-colloidal, and sucralose. The 1.75 mg tablet also contains yellow iron oxide, and the 3.5 mg tablet contains beige iron oxide.</p>
<p><a name="p10274122"></a><span class="Bold"><span class="Emphasis">Rx only</span></span></p>
<p><a name="p10281122"></a>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p><a name="p10284122"></a>Distributed by:<br>Purdue Pharma L.P.<br>Stamford, CT 06901-3431</p>
<p><a name="p10497122"></a>Issued: February 2013</p>
</div>
<div class="Section" data-sectionCode="59845-8">
<a name="Section_19"></a><a name="section-18"></a><p></p>
<h1></h1>
<p class="First"><a name="p10504122"></a><span class="Bold"><span class="Emphasis">Instructions for Use<br>Intermezzo<span class="Sup">Â®</span> (in ter mÃ©t zoh)<br>(zolpidem tartrate) sublingual tablet CIV</span></span></p>
<p><a name="p10519122"></a>Read these Instructions for Use before you start taking Intermezzo and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.</p>
<p><a name="p10522122"></a><span class="Bold"><span class="Emphasis">What is the most important Information I should know about Intermezzo?</span></span></p>
<p><a name="p10529122"></a>Follow these Instructions for Use when you take Intermezzo. If you do not follow these instructions, you might be drowsy in the morning without knowing it.</p>
<ul class="Disc">
<li>Only take 1 tablet a night if needed</li>
<li>Only take Intermezzo if you have at least 4 hours of bedtime left</li>
</ul>
<p><a name="p10540122"></a><span class="Bold"><span class="Emphasis">Using Intermezzo the wrong way can make you drowsy in the morning. </span></span></p>
<p><a name="p10753122"></a><span class="Bold"><span class="Emphasis">Before you go to bed: </span></span></p>
<ul class="Disc">
<li>Place only 1 Intermezzo pouch by your bed, and have a clock or watch nearby (see Figure A). <br><div class="Figure"><img alt="Figure A" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=913b6cfe-1fb0-44a8-817a-26374bbce995&amp;name=figure-a.jpg"></div>
<br><span class="Bold">Figure A</span>
</li>
<li>Store all other unopened Intermezzo pouches with your other medicines away from your bedside.</li>
<li>Only open the Intermezzo pouch when you are ready to use it. </li>
<li>You can either use the <span class="Bold"><span class="Emphasis">Intermezzo Dosing Time Chart</span></span> (see Figure B) or the <span class="Bold"><span class="Emphasis">Dosing Time Tool</span></span> (see Figure C) that comes with Intermezzo to find the latest time during the night you can take Intermezzo. </li>
</ul>
<p><a name="p10789122"></a><span class="Bold"><span class="Emphasis">Intermezzo Dosing Time Chart (see Figure B):</span></span></p>
<ul class="Disc">
<li>You can take Intermezzo if you have at least 4 hours of bedtime left before you must be awake. </li>
<li>Find the earliest time you have to be up and awake in the column on the left. </li>
<li>Find the latest time you can take Intermezzo on the same line in the column on the right.</li>
</ul>
<a name="t11013122"></a><table border="0" cellpadding="1" cellspacing="1" width="60%">
<caption><span>Intermezzo Dosing Time Chart</span></caption>
<colgroup>
<col align="center" width="50%">
<col align="center" width="50%">
</colgroup>
<tfoot><tr class="First Last"><td align="center" colspan="2"><span class="Bold">Figure B</span></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule" align="center">If you must<br>be awake by:</td>
<td class="Botrule" align="center">Take<br>Intermezzo before:</td>
</tr>
<tr>
<td class="Botrule" align="center">4 am</td>
<td class="Botrule" align="center">12 midnight</td>
</tr>
<tr>
<td class="Botrule" align="center">5 am</td>
<td class="Botrule" align="center">1 am</td>
</tr>
<tr>
<td class="Botrule" align="center">6 am</td>
<td class="Botrule" align="center">2 am</td>
</tr>
<tr>
<td class="Botrule" align="center">7 am</td>
<td class="Botrule" align="center">3 am</td>
</tr>
<tr>
<td class="Botrule" align="center">8 am</td>
<td class="Botrule" align="center">4 am</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center">9 am</td>
<td class="Botrule" align="center">5 am</td>
</tr>
</tbody>
</table>
<p><a name="p11297122"></a><span class="Bold"><span class="Emphasis">Intermezzo Dosing Time Tool (see Figure C):</span></span></p>
<ul class="Disc">
<li>Turn the Intermezzo Dosing Time Tool wheel to show the earliest time that you must be awake under the green arrow. 	</li>
<li>Take Intermezzo before the time under the brown arrow.</li>
</ul>
<div class="Figure"><img alt="Figure C" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=913b6cfe-1fb0-44a8-817a-26374bbce995&amp;name=figure-c.jpg"></div>
<p><a name="p11520122"></a><span class="Bold"><span class="Emphasis">During the night when you take Intermezzo:</span></span></p>
<p><a name="p11527122"></a><span class="Bold">Step 1.</span> Check the current time and use the Intermezzo Dosing Time Chart or the Intermezzo Dosing Time Tool to decide if you should take Intermezzo.</p>
<ul class="Disc"><li>Only take Intermezzo if you have at least 4 hours of bedtime left before you have to be awake (see Figure B).</li></ul>
<p><a name="p11538122"></a><span class="Bold">Step 2.</span> Open the Intermezzo pouch you placed by your bed.</p>
<ul class="Disc"><li>Fold the Intermezzo pouch along the dotted line. While the Intermezzo pouch is folded, tear the pouch open at the notch at the center of the dotted line (see Figure D).</li></ul>
<div class="Figure"><img alt="Figure D" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=913b6cfe-1fb0-44a8-817a-26374bbce995&amp;name=figure-d.jpg"></div>
<p><a name="p11551122"></a><span class="Bold">Step 3.</span> Remove the tablet from the Intermezzo pouch.</p>
<p><a name="p11559122"></a><span class="Bold">Step 4.</span> Leave the empty Intermezzo pouch where you can see it. The empty pouch will help remind you that you already took your Intermezzo dose (see Figure E).</p>
<div class="Figure"><img alt="Figure E" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=913b6cfe-1fb0-44a8-817a-26374bbce995&amp;name=figure-e.jpg"></div>
<p><a name="p11567122"></a><span class="Bold">Step 5.</span> While in bed, place the Intermezzo tablet under your tongue and allow it to break apart completely, then swallow. Do not swallow it whole (see Figure F).</p>
<div class="Figure"><img alt="Figure F" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=913b6cfe-1fb0-44a8-817a-26374bbce995&amp;name=figure-f.jpg"></div>
<p><a name="p11781122"></a><span class="Bold">Step 6.</span> Throw the empty Intermezzo pouch away in the morning.</p>
<p><a name="p11787122"></a><span class="Bold"><span class="Emphasis">When you wake up in the morning,</span></span> be sure that at least 4 hours have passed since you have taken Intermezzo and you feel fully awake before driving. Do not do dangerous activities until you know how Intermezzo affects you.</p>
<p><a name="p11795122"></a>This Medication Guide and Instructions for Use have been approved by the U.S. Food and Drug Administration.</p>
<p><a name="p11798122"></a>Distributed by:<br>Purdue Pharma L.P.<br>Stamford, CT 06901-3431</p>
<p><a name="p11805122"></a>Issued: February 2013</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="p2"></a><a name="section-19"></a><p></p>
<p class="First"><a name="p212222222"></a>INTERMEZZO (zolpidem tartrate) sublingual tablets<br>NDC:59011-256<br>Pouch</p>
<div class="Figure"><img alt="INTERMEZZO (zolpidem tartrate) sublingual tablets" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=913b6cfe-1fb0-44a8-817a-26374bbce995&amp;name=175-mg-pouch-sample.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="p3"></a><a name="section-20"></a><p></p>
<p class="First"><a name="p2122333333324524"></a>INTERMEZZO (zolpidem tartrate) sublingual tablets<br>NDC:59011-256<br>Carton</p>
<div class="Figure"><img alt="INTERMEZZO (zolpidem tartrate) sublingual tablets" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=913b6cfe-1fb0-44a8-817a-26374bbce995&amp;name=175-mg-pouch.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="p5"></a><a name="section-21"></a><p></p>
<p class="First"><a name="p212245555555"></a>INTERMEZZO (zolpidem tartrate) sublingual tablets<br>NDC:59011-255<br>Pouch</p>
<div class="Figure"><img alt="INTERMEZZO (zolpidem tartrate) sublingual tablets" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=913b6cfe-1fb0-44a8-817a-26374bbce995&amp;name=35-mg-pouch-sample.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="p6"></a><a name="section-22"></a><p></p>
<p class="First"><a name="p21226676767676"></a>INTERMEZZO (zolpidem tartrate) sublingual tablets<br>NDC:59011-255<br>Carton</p>
<div class="Figure"><img alt="INTERMEZZO (zolpidem tartrate) sublingual tablets" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=913b6cfe-1fb0-44a8-817a-26374bbce995&amp;name=35-mg-pouch.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>INTERMEZZOÂ 		
					</strong><br><span class="contentTableReg">zolpidem tartrate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:59011-256</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBLINGUAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIVÂ Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>zolpidem tartrate</strong> (zolpidem) </td>
<td class="formItem">zolpidem tartrate</td>
<td class="formItem">1.75Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sorbitol</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>crospovidone</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium carbonate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> </strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium stearyl fumarate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sucralose</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ferric oxide yellow</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">SPEARMINT</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">zz</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:59011-256-30</td>
<td class="formItem">30  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 POUCH; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:59011-256-05</td>
<td class="formItem">5  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 POUCH; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022328</td>
<td class="formItem">04/05/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>INTERMEZZOÂ 		
					</strong><br><span class="contentTableReg">zolpidem tartrate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:59011-255</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBLINGUAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIVÂ Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>zolpidem tartrate</strong> (zolpidem) </td>
<td class="formItem">zolpidem tartrate</td>
<td class="formItem">3.5Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sorbitol</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>crospovidone</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium carbonate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> </strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium stearyl fumarate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sucralose</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">SPEARMINT</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">zz</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:59011-255-30</td>
<td class="formItem">30  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 POUCH; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:59011-255-05</td>
<td class="formItem">5  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 POUCH; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022328</td>
<td class="formItem">04/05/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Purdue Pharma LP
							(932323652)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>Purdue Pharma LP (932323652)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Patheon Pharmaceuticals Inc.</td>
<td class="formItem"></td>
<td class="formItem">005286822</td>
<td class="formItem">MANUFACTURE(59011-256, 59011-255)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sharp Corporation</td>
<td class="formItem"></td>
<td class="formItem">002346625</td>
<td class="formItem">PACK(59011-256, 59011-255)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sharp Corporation</td>
<td class="formItem"></td>
<td class="formItem">143696495</td>
<td class="formItem">PACK(59011-256, 59011-255)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>e6069acd-fd6f-4229-a71a-7258a2a35587</div>
<div>Set id: 913b6cfe-1fb0-44a8-817a-26374bbce995</div>
<div>Version: 7</div>
<div>Effective Time: 20150731</div>
</div>
</div>Â <div class="DistributorName">Purdue Pharma LP</div></p>
</body></html>
